<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02587598</url>
  </required_header>
  <id_info>
    <org_study_id>INCB 53914-101</org_study_id>
    <nct_id>NCT02587598</nct_id>
  </id_info>
  <brief_title>Study of INCB053914 in Subjects With Advanced Malignancies</brief_title>
  <official_title>A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, dose-escalation study of the proviral integration site of Moloney
      murine leukemia virus (PIM) kinase inhibitor INCB053914 in subjects with advanced
      malignancies. The study will be conducted in 4 parts. Part 1 (monotherapy dose escalation)
      will evaluate safety and determine the maximum tolerated dose of INCB053914 monotherapy and
      the recommended phase 2 dose(s) (a tolerated pharmacologically active dose that will be taken
      forward into the remaining parts of the study). Part 2 (monotherapy dose expansion) will
      further evaluate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of
      the recommended Phase 2 dose(s). Part 3 (combination dose finding) will evaluate safety of
      INCB053914 in combination with select standard of care (SOC) agents and will identify the
      optimal INCB053914 dose in combination with conventional SOC regimens to take forward into
      Part 4. Part 4 (combination dose expansion) will further evaluate the safety, efficacy and
      pharmacokinetics of the recommended Phase 2 dose combination(s).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 31, 2015</start_date>
  <completion_date type="Anticipated">January 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of the safety and tolerability of INCB053914 as measured by the number of participants with adverse events</measure>
    <time_frame>Approximately 7 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 4 only : Determination of the efficacy of INCB053914 in combination with the intermediate-dose cytarabine (I DAC) in subjects with relapsed or refractory acute myeloid leukemia (AML) based on objective remission rate (ORR)</measure>
    <time_frame>Approximately 2 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 4 only : Determination of the efficacy of INCB053914 in combination with azacitidine in subjects with newly diagnosed AML who are 65 years or older and unfit for intensive chemotherapy based on ORR</measure>
    <time_frame>Approximately 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations oF INCB053914 will be determined by the use of validated assays</measure>
    <time_frame>approximately 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic profile of INCB053914 determined by phosphorylation of Bcl-2-associated death promoter protein</measure>
    <time_frame>approximately 1 month</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">97</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>INCB053914</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>INCB053914 + Azacitidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>INCB053914 + I-DAC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>INCB053914 + Ruxolitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INCB053914</intervention_name>
    <description>Initial cohort dose of INCB053914 at the protocol-specified starting dose in two treatment groups in dose escalation, with subsequent expansion in up to five cohorts based on protocol-specific criteria.
INCB053914 tablets to be administered by mouth.</description>
    <arm_group_label>INCB053914</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INCB053914</intervention_name>
    <description>Initial cohort dose of INCB053914 at the protocol-specified starting dose. INCB053914 tablets to be administered by mouth.</description>
    <arm_group_label>INCB053914 + Azacitidine</arm_group_label>
    <arm_group_label>INCB053914 + I-DAC</arm_group_label>
    <arm_group_label>INCB053914 + Ruxolitinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>I-DAC (Intermediate dose cytarabine)</intervention_name>
    <description>Cytarabine dose will be 1 g/m^2. Cytarabine will be administered as an intravenous (IV) infusion.</description>
    <arm_group_label>INCB053914 + I-DAC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>Azacitidine dose will be 75 mg/m^2. Azacitidine will be administered either sub-cutaneously (SC) or intravenously (IV).</description>
    <arm_group_label>INCB053914 + Azacitidine</arm_group_label>
    <other_name>Vidaza®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ruxolitinib</intervention_name>
    <description>Starting dose of ruxolitinib will be the dose the subject was on at study entry Ruxolitinib will be administered by mouth.</description>
    <arm_group_label>INCB053914 + Ruxolitinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 18 years or older

          -  Confirmed diagnosis of select advanced malignancy

          -  Parts 1 and 2:

               -  Unresponsive to currently available therapy and there is no standard-of-care
                  therapy available in the judgment of the investigator.

               -  Not currently a candidate for curative treatment

          -  Parts 3 and 4:

               -  Subjects with relapsed/refractory AML must have received either induction
                  chemotherapy for AML or hypomethylating agents for hematologic disease before
                  AML.

               -  Elderly subjects (≥ 65 years) with newly diagnosed AML must be treatment naive
                  and unfit for intensive chemotherapy.

               -  Myelofibrosis subjects must have been treated with ruxolitinib for ≥ 6 months
                  with a stable dose for ≥ 8 weeks (acceptable doses are 5 mg twice daily [BID] to
                  25 mg BID).

          -  Willingness to undergo a pretreatment bone marrow biopsy and/or aspirate, or archival
             sample obtained since completion of most recent therapy (as appropriate to subjects
             with existing bone marrow disease or for whom bone marrow examination is a component
             of disease status assessment)

          -  Eastern Cooperative Oncology Group (ECOG) performance status

               -  Part 1: 0 or 1

               -  Parts 2, 3 and 4: 0, 1, or 2

          -  Life expectancy &gt; 12 weeks or ≥ 24 weeks for Part 3 and Part 4 MF subjects.

        Exclusion Criteria:

          -  Inadequate bone marrow or organ function

          -  Received an investigational agent within 5 half-lives or 14 days, whichever is longer,
             prior to receiving the first dose of study drug

          -  Received non-biologic anticancer medication within 5 half-lives prior to receiving the
             first dose of study drug (within 6 weeks for mitomycin-C or nitrosoureas), within 28
             days for any antibodies or biological therapies

          -  Prior receipt of a PIM inhibitor

          -  Any history of disease involving the central nervous system (Part 1). Known active
             disease involving the central nervous system (Part 2).

          -  Screening corrected QT interval (QTc) interval &gt; 470 milliseconds

          -  Radiotherapy within the 2 weeks prior to initiation of treatment

          -  Chronic or current active infection requiring systemic antibiotic, antifungal, or
             antiviral treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fred Zheng, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Incyte Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85719</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Davis comprehensive Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Medical Hematology &amp; Oncology</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists &amp; Research Institute</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>33916</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center &amp; Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University-Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>69198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Care Clinical Trials LLC</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stephenson Cancer Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 26, 2015</study_first_submitted>
  <study_first_submitted_qc>October 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2015</study_first_posted>
  <last_update_submitted>July 17, 2020</last_update_submitted>
  <last_update_submitted_qc>July 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>leukemia</keyword>
  <keyword>myelodysplastic syndrome (MDS)</keyword>
  <keyword>myelodysplastic/myeloproliferative neoplasms (MDS/MPN)</keyword>
  <keyword>myelofibrosis (MF)</keyword>
  <keyword>lymphoproliferative disorders</keyword>
  <keyword>acute myeloid leukemia (AML)</keyword>
  <keyword>lymphomas</keyword>
  <keyword>multiple myeloma (MM)</keyword>
  <keyword>PIM kinases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

